References
- Coppola A, Di Capua M, Di Minno MN, et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183–95. doi: 10.2147/JBM.S6885.
- Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; (9): Cd003429. doi: 10.1002/14651858.cd003429.pub4.
- Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357(6): 535–44. doi: 10.1056/NEJMoa067659.
- Langley AR, Stain AM, Chan A, et al. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia 2015; 21(4): 469–76. doi: 10.1111/hae.12713.
- Rodriguez V, Mancuso ME, Warad D, et al. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study. Haemophilia 2015; 21(5): e369–e74. doi: 10.1111/hae.12740.
- DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 Suppl 1: 1–22. doi: 10.1111/j.1365-2516.2007.01497.x.
- Vepsäläinen K, Lassila R, Arola M, et al. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. Haemophilia 2015; 21(6): 747–53. doi: 10.1111/hae.12665.
- Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10(2): 134–46. doi: 10.1046/j.1365-2516.2003.00840.x.
- Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004; 18(2): 93–100. doi: 10.1016/S0268-960X(03)00043-2.
- Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6(2): 66–70. doi: 10.1046/j.1365-2516.2000.00381.x.
- Neunert CE, Miller KL, Journeycake JM, Buchanan GR. Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. Haemophilia 2008; 14(2): 260–70. doi: 10.1111/j.1365-2516.2007.01605.x.
- Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1–158. doi: 10.1111/hae.14046.
- Minna K, Anne M, Beatrice N, Rainer K, Susanna R. Correction of haemostasis can be reduced to four days for CVAD implantation in severe haemophilia A patients: Data from the PedNet study group. Haemophilia 2021; 27(3): 392–7. doi: 10.1111/hae.14231.
- Hagglof H, Magnusson M, Petrini P, Frisk T, Ranta S. Perioperative haemostasis in children with haemophilia and inhibitors during central venous catheter surgery: The Karolinska model. Haemophilia 2018; 24(5): e380–e3. doi: 10.1111/hae.13594.